CTMX FY 2020 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CTMXCytomX Therapeutics, Inc.

$822M

FY 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$68M+19.0% YoY

Gross Profit

$68M100.0% margin

Operating Income

-$81M-117.7% margin

Net Income

-$65M-94.7% margin

EPS (Diluted)

$-0.71

Cash Flow

Operating Cash Flow

$5M

Free Cash Flow

$3M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$359M

Total Liabilities

$366M

Stockholders' Equity

-$8M

Cash & Equivalents

$192M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$68M	$57M	+19.0%
Gross Profit	$68M	$57M	+19.0%
Operating Income	-$81M	-$111M	+27.4%
Net Income	-$65M	-$102M	+36.6%